IL273805A - Preparations and methods for the treatment of diffuse large b-cell lymphoma - Google Patents
Preparations and methods for the treatment of diffuse large b-cell lymphomaInfo
- Publication number
- IL273805A IL273805A IL273805A IL27380520A IL273805A IL 273805 A IL273805 A IL 273805A IL 273805 A IL273805 A IL 273805A IL 27380520 A IL27380520 A IL 27380520A IL 273805 A IL273805 A IL 273805A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- cell lymphoma
- diffuse large
- treating diffuse
- Prior art date
Links
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 title 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/055667 WO2019075366A1 (en) | 2017-10-13 | 2018-10-12 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL273805A true IL273805A (en) | 2020-05-31 |
Family
ID=64110107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273805A IL273805A (en) | 2017-10-13 | 2020-04-05 | Preparations and methods for the treatment of diffuse large b-cell lymphoma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (enExample) |
| EP (1) | EP3694520A1 (enExample) |
| JP (2) | JP2020536923A (enExample) |
| KR (1) | KR20200068655A (enExample) |
| CN (1) | CN111212646A (enExample) |
| AU (1) | AU2018347457A1 (enExample) |
| BR (1) | BR112020007203A2 (enExample) |
| CA (1) | CA3075291A1 (enExample) |
| CL (1) | CL2020000973A1 (enExample) |
| EA (1) | EA202090565A1 (enExample) |
| IL (1) | IL273805A (enExample) |
| MX (2) | MX2020003395A (enExample) |
| SG (1) | SG11202002374RA (enExample) |
| TW (1) | TW201922283A (enExample) |
| WO (1) | WO2019075366A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP4118113A1 (en) * | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| JP2023545135A (ja) * | 2020-10-12 | 2023-10-26 | グレフェックス， インコーポレイテッド | ＳＡＲＳ－ＣｏＶタンパク質発現細胞に対するＴ細胞応答を標的にする抗体コンストラクト、それらの設計および使用 |
| CN120390650A (zh) * | 2022-11-01 | 2025-07-29 | 坦尼奥第二公司 | 治疗非霍奇金淋巴瘤的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| MA44699A (fr) | 2015-05-29 | 2021-05-05 | Merck Sharp & Dohme | Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer |
| US10973822B2 (en) * | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en not_active Ceased
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/ko not_active Ceased
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/pt unknown
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en not_active Abandoned
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/ja active Pending
- 2018-10-12 EA EA202090565A patent/EA202090565A1/ru unknown
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/es unknown
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en not_active Withdrawn
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en not_active Abandoned
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/zh active Pending
- 2018-10-15 TW TW107136236A patent/TW201922283A/zh unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/es unknown
- 2020-07-13 MX MX2024001888A patent/MX2024001888A/es unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200262919A1 (en) | 2020-08-20 |
| AU2018347457A1 (en) | 2020-04-09 |
| CL2020000973A1 (es) | 2020-12-28 |
| JP2024001071A (ja) | 2024-01-09 |
| EP3694520A1 (en) | 2020-08-19 |
| CA3075291A1 (en) | 2019-04-18 |
| TW201922283A (zh) | 2019-06-16 |
| CN111212646A (zh) | 2020-05-29 |
| BR112020007203A2 (pt) | 2020-10-20 |
| KR20200068655A (ko) | 2020-06-15 |
| MX2024001888A (es) | 2024-02-29 |
| EA202090565A1 (ru) | 2020-10-13 |
| SG11202002374RA (en) | 2020-04-29 |
| MX2020003395A (es) | 2020-08-03 |
| JP2020536923A (ja) | 2020-12-17 |
| WO2019075366A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295611B1 (en) | Method and device for processing tissues and cells | |
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
| EP3331582A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS | |
| SG11202005062SA (en) | Electrochemical methods, devices and compositions | |
| IL268058B1 (en) | Compositions and methods for depleting cd137 plus cells | |
| LU92752B1 (en) | Cell culture apparatus and culture methods using same | |
| IL274837A (en) | Methods and preparations for the treatment of cancer | |
| GB201611535D0 (en) | Methods and compositions for treating cancer with siglec-9 activity modulators | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| PL3261644T3 (pl) | Kompozycje i sposoby leczenia degradacji siatkówki | |
| DK3658142T3 (en) | Compositions and methods for treating galactosemia | |
| IL273805A (en) | Preparations and methods for the treatment of diffuse large b-cell lymphoma | |
| IL271256A (en) | Preparations and methods for the treatment of teopathy | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL275028A (en) | Preparation and method for the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma | |
| ZA202001921B (en) | Pharmaceuticals composition for treating keloid and uses thereof | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| IL273934A (en) | Methods for treating contractured muscle and related cultured cells | |
| IL272782A (en) | Preparations and methods for the treatment of cancer | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| GB2539478B (en) | Electrochemical cell and process | |
| EP3268028A4 (en) | Compositions and methods for treating cancer |